|
|
 |
|
Viewing report
|
|
|
|
Medicated Skin Products Market in the Netherlands to 2014 (OTC Healthcare)
Datamonitor, Feb 2011, Pages: 28
Introduction
This databook provides key data and information on the Medicated Skin Products Market in the Netherlands (OTC Healthcare). This report is a comprehensive resource for market, category and segment level data including value, volume, distribution share and company & brand share. This report also provides expenditure and consumption data for the historic and forecast periods.
Scope
-Market,category and segment level information on value, volume, and expenditure & consumption, with historic (2003-2008) and forecast (2009-2013) data
-Category level company and brand share as well as distribution share information for 2007 and 2008
Highlights
The medicated skin products category was valued at €62m ($90.9m) in 2009, representing a CAGR of 4.3% since 2004.
By the end of 2014, the medicated skin products category will be worth €75.6m ($110.7m), with an expected CAGR of 4% between 2009 and 2014.
The medicated skin products market was led by anti-bacterials (representing 28.2% of the total value) followed by other medicated skin products and disinfectants, with a 20.9% and 19.5% market share, respectively. Acne treatments and anti-fungals constitute the remaining segments with an 18.2% and 13.2% market share, respectively.
Omega Pharma NV is the market leader with a 32.2% share of the market.
Reasons to Purchase
-Develop business strategies by understanding the quantitative trends within the Medicated Skin Products Market in the Netherlands (OTC Healthcare)
-Design effective marketing and sales strategies by identifying key market categories and segments
-Identify key players within the market to plan lucrative M&A, partnerships and agreements
|
|
|
|
